At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 81 enrolled
Drug / intervention
Ranibizumab 0.5mg (monthly) +3 moredrug
Likely dose
Ranibizumab 0.5mg (monthly)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach(RELATE)
In Brief
A Phase 2 clinical trial evaluating Ranibizumab 0.5mg (monthly), Ranibizumab 2.0mg (monthly), and 2 other interventions for Retinal Vein Occlusion. Completed, enrolled 81 participants across 1 site.
Detailed Summary
The primary Objective of this study is to evaluate the safety and tolerability of intraocular injections of 0.5mg or 2.0mg of ranibizumab in patients with macular edema due to retinal vein occlusion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRetinal Vein Occlusion
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2009
Enrollment StartNov 2009
Primary CompletionApr 2015
TodayJul 2026
First PostedOct 28, 2009
Enrollment StartNov 1, 2009
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 16.7 years ago
Interventions
Ranibizumab 0.5mg (monthly)drug
Branch retinal vein occlusion- Intravitreal injection of 0.5mg ranibizumab alone
Ranibizumab 2.0mg (monthly)drug
Pro re nata (prn) ranibizumabdrug
Pro re nata (prn) Laser photocoagulationprocedure